TBM100
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Novartis Pharmaceuticals
Overview
TBM100 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
TBM100 clinical trials
Explore related
Medical disclaimer. This page summarizes research about TBM100 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.